These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 25879675)

  • 1. Raltegravir plus two nucleoside analogues as combination antiretroviral therapy in HIV-infected patients who require cancer chemotherapy.
    Casado JL; Machuca I; Bañón S; Moreno A; Moltó J; Rodriguez MA
    Antivir Ther; 2015; 20(7):773-7. PubMed ID: 25879675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy.
    Bañón S; Machuca I; Araujo S; Moreno A; Perez-Elías MJ; Moreno S; Casado JL
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19590. PubMed ID: 25394095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.
    Loulergue P; Merad M; Coriat R; Ducreux M; Planchard D; Boige V; Le Cesne A; Gregory TM; Poinsignon V; Paci A; Mir O
    Invest New Drugs; 2017 Apr; 35(2):247-249. PubMed ID: 27838867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma.
    Simonelli C; Zanussi S; Cinelli R; Dal Maso L; Di Gennaro G; D'Andrea M; Nasti G; Spina M; Vaccher E; De Paoli P; Tirelli U
    Clin Infect Dis; 2003 Sep; 37(6):820-7. PubMed ID: 12955644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
    Casado JL; Bañón S; Rodriguez MA; Moreno A; Moreno S
    Antiviral Res; 2015 Jan; 113():103-6. PubMed ID: 25460844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia.
    Xiao H; Xue Y; Gu S; Wang J; Sun H; Lu H
    Biosci Trends; 2016 Feb; 10(1):42-6. PubMed ID: 26911541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Kaposi sarcoma in HIV patients: Response to antiretroviral treatment and chemotherapy].
    Lasso M; Pérez J; Noriega L; Malebrán A; Espinoza S
    Rev Med Chil; 2003 May; 131(5):483-90. PubMed ID: 12879808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
    Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study.
    Buchacz K; Wiegand R; Armon C; Chmiel JS; Wood K; Brooks JT; Palella FJ
    HIV Clin Trials; 2015 Aug; 16(4):139-46. PubMed ID: 26126549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
    Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
    Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AIDS-related systemic non-Hodgkin's lymphoma at a large community program.
    Vilchez RA; Kozinetz CA; Jorgensen JL; Kroll MH; Butel JS
    AIDS Res Hum Retroviruses; 2002 Mar; 18(4):237-42. PubMed ID: 11860669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
    Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
    Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
    Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
    Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.
    Fraunholz I; Weiss C; Eberlein K; Haberl A; Rödel C
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1425-32. PubMed ID: 19744801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
    Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
    Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.
    Mata-Marín JA; Smeke AE; Rodriguez MR; Chávez-García M; Banda-Lara MI; Rios AM; Nuñez-Rodríguez N; Domínguez-Hermosillo JC; Sánchez AC; Juarez-Kasusky I; Herrera JE; Ramírez JL; Gaytán-Martínez J
    Drugs R D; 2017 Mar; 17(1):225-231. PubMed ID: 28124232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age Study.
    Pavone P; Giustini N; Fimiani C; Paoletti F; Falciano M; Salotti A; Di Sora F; Al Moghazi S; Mezzaroma I; Vullo V; d'Ettorre G
    Curr HIV Res; 2017 Nov; 15(5):355-360. PubMed ID: 28969567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
    Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.